Pro Medicus Ltd (PME)

Currency in AUD
306.41
-0.50(-0.16%)
Closed·
PME Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
PME is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
302.55307.90
52 wk Range
146.39336.00
Key Statistics
Bid/Ask
305.00 / 308.00
Prev. Close
306.91
Open
306.1
Day's Range
302.55-307.9
52 wk Range
146.39-336
Volume
110.87K
Average Volume (3m)
174.64K
1-Year Change
103.19%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PME Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
316.56
Upside
+3.31%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Pro Medicus Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Pro Medicus Ltd Company Profile

Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease, a mobile application that provides users access to medical imaging results; and Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.

Compare PME to Peers and Sector

Metrics to compare
PME
Peers
Sector
Relationship
P/E Ratio
277.8x−6.6x−0.6x
PEG Ratio
7.09−0.090.00
Price/Book
124.6x2.5x2.6x
Price / LTM Sales
150.3x4.0x3.3x
Upside (Analyst Target)
4.7%89.7%37.9%
Fair Value Upside
Unlock22.0%3.7%Unlock

Analyst Ratings

4 Buy
8 Hold
3 Sell
Ratings:
15 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 316.56
(+3.31% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.10%
Dividend Yield
0.18%
Industry Median 0.80%
Annualised payout
0.55
Paid unevenly
5-Years Growth
+35.59%
Growth Streak

Earnings

Latest Release
Aug 13, 2025
EPS / Forecast
0.61 / 0.576
Revenue / Forecast
115.79M / 113.22M
EPS Revisions
Last 90 days

PME Income Statement

People Also Watch

216.60
CSL
-4.16%
301.91
COH
-0.62%
109.34
HUB
+1.78%
112.59
WTC
-1.76%
167.98
XRO
-0.60%

FAQ

What Stock Exchange Does Pro Medicus Ltd Trade On?

Pro Medicus Ltd is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Pro Medicus Ltd?

The stock symbol for Pro Medicus Ltd is "PME."

What Is the Pro Medicus Ltd Market Cap?

As of today, Pro Medicus Ltd market cap is 31.97B.

What Is Pro Medicus Ltd's Earnings Per Share (TTM)?

The Pro Medicus Ltd EPS (TTM) is 1.10.

From a Technical Analysis Perspective, Is PME a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Pro Medicus Ltd Stock Split?

Pro Medicus Ltd has split 0 times.

How Many Employees Does Pro Medicus Ltd Have?

Pro Medicus Ltd has 132 employees.

What is the current trading status of Pro Medicus Ltd (PME)?

As of 23 Aug 2025, Pro Medicus Ltd (PME) is trading at a price of 306.41, with a previous close of 306.91. The stock has fluctuated within a day range of 302.55 to 307.90, while its 52-week range spans from 146.39 to 336.00.

What Is Pro Medicus Ltd (PME) Price Target According to Analysts?

The average 12-month price target for Pro Medicus Ltd is AUD316.55857, with a high estimate of AUD350 and a low estimate of AUD220. 4 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an +3.31% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.